SAN DIEGO, January 8, 2010 / PRNewswire-FirstCall /-AltheaDx, Inc. - http://www.altheadx.com - announced today the formation of a strategic partnership with compendia Bioscience to combine their respective core competencies in assay development, validation and bioinformatics. The two companies will together create innovative products and services that focuses on cancer biomarker discovery and subsequent development of testing predict patient outcomes in clinical trials. As of 2006 has AltheaDx FFPE of tissue-based biomarkers discovery and companion diagnostic development allows. AltheaDx has facilitated the clinical use of biomarkers through validation and clinical example tests under GLP and/or CLIA.
Compendia Bioscience co-founder and CEO, said Dan Rhodes, "AltheaDx has since its inception with very deep technical skills in genetic analysis a pioneering developer of PCR-based assays in clinical settings." "We are thrilled by this new strategic partnership."
The inaugural launch of the strategic partnership is the breast cancer segregation Panel ™ assay. This test is a real time PCR based, optimized for the analysis of RNA from formalin-fixed, paraffin-embedded (FFPE) tissue extracts. This Panel measures 96 genes in a proprietary meta-analysis of cancer genomic data from more than 5,000 clinical samples to identify. AltheaDx processed and San Diego-based CLIA/GLP laboratory to analyse, to patient during compendia Bioscience downstream data analysis and statistical correlation results in clinical studies succeed samples in your will.
"We are thrilled to announce this new partnership with compendia Bioscience," said François Ferré, co-founder and CEO of AltheaDx. "The recognized leader in cancer genomic data into meaningful information relating to patient outcomes in clinical trials is to translate compendia Bioscience." "The compendia's powerful bioinformatics platform is very valuable content provide to develop predictive checks we can for our pharmaceutical partners."
Under the terms of the partnership, the companies to develop segregation panels for other types of cancer plan. The next assay, colorectal cancer segregation Panel ™, will be released in 2011.
About AltheaDx, Inc.
AltheaDx, a leading San Diego based diagnostic development and testing company, provides clinical biomarker discovery, development and validation services to support researchers worldwide in their efforts to genomic information for the development of novel therapies use the assay. AltheaDx plays to discover a critical role in pharmaceutical and specify validation of biomarkers that can response, predictions and seamless to an efficient commercialization path for the tests on the market. The AltheaDx aims to most to mitigate risk, reduce costs for therapeutic development for pharmaceutical partners.
For more information, visit www.altheadx.com
About compendia Bioscience, Inc.
Compendia Bioscience is dedicated to the application of the global collection of cancer of genomic data to patient care by enabling discovery and development of better cancer diagnosis and treatment of. www.compendiabio.com
Please contact for further information:
Associate Director, corporate development
SOURCE AltheaDx, Inc.
Back to topRELATED LINKS
http://www.altheadx.com
http://www.compendiabio.com
No comments:
Post a Comment